A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The main purpose of this study is to evaluate the efficacy and safety of sintilimab plus ramucirumab compared to stand of care first-line chemotherapy in participants with advanced gastric or esophagogastric adenocarcinoma.
Epistemonikos ID: 2fa90529ee3d2b1384aa2b19a891768d7731a69b
First added on: May 08, 2024